Cocrystal Pharma, Inc.
As of Oct 22, 2026, Cocrystal Pharma is in Stage 2, the uptrend phase, now in week 3 (since Oct 5, 2026). It closed at $0.91, 42.0% below its 52-week high and below its 200-day average, which is rising.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is COCP early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
COCP among Biotechnology226th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …226 | COCP | Stage 2 · wk 3 | 44 | −23.5% |
Cocrystal Pharma: quick answers
What stage is Cocrystal Pharma in?
As of Oct 22, 2026, Cocrystal Pharma (COCP) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 5, 2026 and is in week 3. What the four stages mean
Is Cocrystal Pharma in an uptrend?
Yes. Cocrystal Pharma is in a Stage 2 uptrend. It trades 17.7% below its 200-day average, which is rising.
How far is Cocrystal Pharma from its 52-week high?
Cocrystal Pharma closed at $0.91 on Oct 22, 2026, 42.0% below its 52-week high of $1.57. Its 52-week low is $0.82.
How has Cocrystal Pharma performed over the past year?
As of Oct 22, 2026, Cocrystal Pharma is down 14.2% over the past year and down 8.1% so far in 2026.
Which sector and industry is Cocrystal Pharma in?
Cocrystal Pharma is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.